Recent Publications

Traber PG, Chou H, Zomer E, Hong F, Klyosov A, et al. (2013) Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease. PLOS ONE 8(10): e75361. doi:10.1371/journal.pone.0075361 (PDF)

Traber PG, Zomer E (2013) Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors. PLOS ONE 8(12): e83481. doi:10.1371/journal.pone.0083481 (PDF)

Klyosov AA, Traber PG. In Galectins and Disease Implications for Targeted Therapeutics. ACS Symposium Series; American Chemical Society: Washington, DC, 2012. (PDF)

Other Company Publications

Klyosov AA, Platt D, Zomer E. Preclinical Studies of Anticancer Efficacy of 5-Fluorouracil when Co-Administered with the 1,4-β-D-Galactomannan. PRECLINICA, 1, 175-186, 2003. (PDF)

Miller MC, Klyosov AA, Platt D, Mayo KH. Using Pulse Field Gradient NMR diffusion measurements to define molecular weight distributions in glycan preparations. Carbohydrate Research, 344, 1205-1212, 2009. (PDF)

Miller MC, Klyosov AA, Mayo KH. Structural Features for α-Galactomannan Binding to Galectin-1. Glycobiology, Vol 0, No. 0. Pp 1-9, 2011. (PDF)

Miller MC, Nesmelova IV, Platt D, Klyosov AA, Mayo KH. The Carbohydrate-binding Domain on Galectin-1 is More Extensive for a Complex Glycan than for Simple Saccharides: Implications for Galectin-glycan Interactions at the Cell Surface. Biochem. J. 421, 211-221, 2009. (PDF)

Miller MC, Klyosov AA, Mayo KH. The α-galactomannan Davanat Binds Galectin-1 at a Site Different from the Conventional Galectin Carbohydrate Binding Domain. Glycobiology, 19, No. 9, 1034-1045, 2009. (PDF)